Characterization of a new CDC73 missense mutation that impairs Parafibromin expression and nucleolar localization.
Mutations of the Cell Division Cycle 73 (CDC73) tumor suppressor gene (previously known as HRPT2), encoding for parafibromin, are associated with the Hyperparathyroidism-Jaw Tumor (HPT-JT) syndrome, an autosomal dominant disease whose clinical manifestations are mainly parathyroid tumors and, less frequently, ossifying fibromas of the jaws, uterine and renal tumors. Most mutations of CDC73 are nonsense or frameshift, while missense mutations are rare and generally affect the N-terminal domain of parafibromin, a region that is still poorly characterized. The aim of this study was to characterize a novel somatic CDC73 missense mutation (Ile60Asn) identified in the mandibular tumor of a HPT-JT patient carrying a germline CDC73 inactivating mutation. Immunostaining of the tumor showed reduced nuclear parafibromin immunoreactivity. Western blotting and confocal microscopy of transfected cells demonstrated that the Ile60Asn mutant parafibromin was less expressed than the wild-type protein and exhibited impaired nucleolar localization. Treatment of transfected cells with translation and proteasome inhibitors demonstrated a decreased stability of the Ile60An mutant, partially due to an increase in proteasomal degradation. Overexpression of the Ile60Asn mutant led to increased cell proliferation and to accumulation in the G2/M phase of cell cycle. Moreover, mutant parafibromin lost the ability to down-regulate c-myc expression. In conclusion, our study shows that a missense mutation in the N-terminus of parafibromin, identified in an ossifying fibroma from a HPT-JT patient, stimulated cell proliferation and impaired parafibromin expression and nucleolar localization, suggesting a relevant role of the N-terminal domain for parafibromin function.
Department of Molecular Medicine, University of Padova, Padova, Italy.
Giulia
G
Masi
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Maurizio
M
Iacobone
Department of Molecular Medicine, University of Padova, Padova, Italy; Istituto Oncologico Veneto IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), Padova, Italy.
Alessandro
A
Sinigaglia
Department of Molecular Medicine, University of Padova, Padova, Italy.
Barbara
B
Mantelli
Department of Medicine, University of Padova, Padova, Italy.
Gianmaria
G
Pennelli
Department of Molecular Medicine, University of Padova, Padova, Italy.
Ignazio
I
Castagliuolo
Department of Molecular Medicine, University of Padova, Padova, Italy.
Giorgio
G
Palù
Department of Molecular Medicine, University of Padova, Padova, Italy.
Luisa
L
Barzon
D001483:Base Sequence; D049109:Cell Proliferation; D004252:DNA Mutational Analysis; D017931:DNA Primers / Q000235:genetics; D005434:Flow Cytometry; D005786:Gene Expression Regulation / Q000235:genetics*; D006367:HeLa Cells; D006801:Humans; D007150:Immunohistochemistry; D018613:Microscopy, Confocal; D008856:Microscopy, Fluorescence; D008969:Molecular Sequence Data; D020125:Mutation, Missense / Q000235:genetics*; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017422:Sequence Analysis, DNA; D025521:Tumor Suppressor Proteins / Q000235:genetics* / Q000378:metabolism*
C454900:CDC73 protein, human; D017931:DNA Primers; D025521:Tumor Suppressor Proteins